August 23rd, 2017
Immunovia Interim report, January-June 2017

“During Q2 we announced that we are establishing our American office in Boston. The head office for the US includes our own reference laboratory that complements our earlier collaboration with Knight Diagnostic Laboratories and gives us delivery capacity in both the east and west of the United States.”

“Another highlight for Immunovia during the quarter was the excellent results from the study of differentiation of Rheumatoid Arthritis (RA), Sjögren’s Syndrome and Systemic Vasculitis. These results complement the ones from the earlier differential study that we presented for SLE in Q1. They further confirm that our IMMrayTM platform is generally applicable for many unsolved clinical problems within both cancer and autoimmunity while specifically strengthening our possibilities in the autoimmunity field.”

“During the quarter we announced that, together with Knight Cancer Institute at OHSU, we received a research grant from PanCAN, a patient advocacy group, to support a retroactive analysis of American patients who developed pancreatic cancer after being diagnosed with diabetes.”

Click to download full report in English (PDF)

Key Indicators
(SEK 000 unless otherwise stated)
1 Apr-30 Jun
2017
1 Apr-30 Jun
2016
 1 Jan-30 Jun
2017
 1 Jan-30 Jun
2016
 2016
Full year
 Net sales 68 66  95  66 177
 Operating earnings -10 645 -2 967 -18 515  -5 403 -14 978
 Earnings before tax -10 554 -2 892 -18 515  -5 298 -14 723
 Net earnings -10 554 -2 892 -18 515 -5 298 -14 723
 Earnings per share before and after dilution (SEK/share) -0,63 -0.20  -1,09 -0,37  -0,98
30 Jun 2017 30 Jun 2016 31 Dec 2016
Equity ratio, % 96 93 96 93 98
No. of shares at the end of the period 16 804 059 14 291 216 16 804 059 14 291 216 16 804 059
Average number of shares before and after dilution 16 804 059 14 291 216 16 804 059 14 291 216 16 804 059

This financial statement has been produced in accordance with IFRS for the Immunovia Group, which comprises Immunovia AB and the wholly-owned subsidiary Immunovia Inc.

 

Outlook*
Immunovia is focused on fundamentally transforming diagnosis of complex forms of cancer and autoimmune diseases. The antibody-based platform, IMMrayTM, is the result of 15 years of research at CREATE Health – the Center for Translational Cancer Research at Lund University, Sweden. IMMrayTM is a technology platform for the development of diagnostic tests and the company’s primary test. IMMrayTM PanCan-d is the first test in the world for early diagnosis of pancreatic cancer.

– It is planned to launch IMMrayTM PanCan-d on the American and European markets with sales to out-of-pocket customers, to start when the accreditation and production upscaling have been completed, with revenues expected to begin in 2018. In coming years Immunovia will address a market that in total is worth around SEK 30 billion.

– Immunovia sees great potential in the development of tests for other unsolved problems in cancer and autoimmune diseases via its IMMrayTM platform. The next focus area will be tests within SLE, based on the positive results announced in early 2017.


For further information, please contact:

Mats Grahn, CEO, Immunovia AB
Phone: +46 (0) 70-532 02 30
E-mail: mats.grahn@immunovia.com

About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer.  In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)

This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above.

Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.

###